NMO Spectrum Disorder Clinical Trials

10 recruiting

NMO Spectrum Disorder Trials at a Glance

10 actively recruiting trials for nmo spectrum disorder are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Beijing, Tianjin, and Bochum. Lead sponsors running nmo spectrum disorder studies include Beijing Tiantan Hospital, Tianjin Medical University General Hospital, and Shanghai Pharmaceuticals Holding Co., Ltd.

Browse nmo spectrum disorder trials by phase

Treatments under study

About NMO Spectrum Disorder Clinical Trials

Looking for clinical trials for NMO Spectrum Disorder? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NMO Spectrum Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NMO Spectrum Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Not Applicable

Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMO Spectrum Disorder
Tang-Du Hospital12 enrolled1 locationNCT07377305
Recruiting

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Multiple SclerosisClinically Isolated SyndromeNMO Spectrum Disorder+2 more
icometrix7,000 enrolled3 locationsNCT06280755
Recruiting

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD

NMO Spectrum Disorder
Tongji Hospital200 enrolled1 locationNCT06885957
Recruiting
Early Phase 1

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

NMO Spectrum Disorder
Shanghai Pharmaceuticals Holding Co., Ltd45 enrolled4 locationsNCT05145361
Recruiting
Phase 1Phase 2

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197
Recruiting

Biorepository and Registry for Plasma Exchange Patients

NMO Spectrum DisorderCIDPAntibody-mediated Rejection+1 more
Charles M Knudson200 enrolled1 locationNCT05004493
Recruiting

Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)

MRIMultiple SclerosisNMO Spectrum Disorder+1 more
Beijing Tiantan Hospital1,000 enrolled1 locationNCT04106830
Recruiting
Phase 1Phase 2

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

NMO Spectrum Disorder
Tianjin Medical University General Hospital12 enrolled1 locationNCT05792462
Recruiting

National, Multicentric Registry Study on Neuroimmunological Diseases in China

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+3 more
Xuanwu Hospital, Beijing7,000 enrolled1 locationNCT06443333
Recruiting

China National Registry of Neuro-Inflammatory Diseases

Multiple SclerosisClinically Isolated SyndromeAcute Disseminated Encephalomyelitis+4 more
Beijing Tiantan Hospital10,000 enrolled1 locationNCT05154370